Therapeutic Strategies for the Management of HCV/HIV co-

HCV/HIV 合并治疗的治疗策略

• 批准号: 7299927
• 负责人: Shyamasundaran Kottilil
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7299927
• 关键词: Therapeutic; Strategies; Management; HCV; HIV

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the management of HIV-infected patients has become increasingly complex. We are conducting studies that: (1) define the role of Hepatitis C viral response to pegylated interferon-based therapy (2) evaluate novel therapeutic strategies in the management of Hepatitis C virus among HIV co-infected individuals, and (3) develop novel genomic and proteomic markers that predict Hepatitis C viral response to existing and newer therapies. Analyses of the kinetics of the viral response to Hepatitis C therapy in Hepatitis C/HIV co-infected individuals suggest that it may be possible to predict long term response to anti-Hepatitis C therapy based on the initial response of the level of Hepatitis C virus in the plasma. Using combination therapy of pegylated interferon together with ribavirin in these subjects, we are determining whether genomic and proteomic markers can predict response to therapy prior to initiation of treatment. Another clinical trial will determine whether more frequent doses of pegylated interferon in combination with ribavirin can enhance the viral kinetic response to Hepatitis C therapy in persons with Hepatitis C infection and HIV infection. A new clinical trial using albumin-conjugated interferon alpha (Albuferon) to treat Hepatitis C among HIV infected patients will begin enrollment later this year.

HIV-1 感染的治疗和监测方面的最新进展已大大减少了与 HIV 相关的疾病和死亡率；然而，艾滋病毒感染者的管理变得越来越复杂。我们正在进行的研究是：(1) 确定丙型肝炎病毒对基于聚乙二醇化干扰素的治疗的反应的作用 (2) 评估在 HIV 合并感染者中管理丙型肝炎病毒的新治疗策略，以及 (3) 开发新的治疗策略预测丙型肝炎病毒对现有和更新疗法的反应的基因组和蛋白质组标记。对丙型肝炎/HIV 共感染个体中丙型肝炎治疗病毒反应动力学的分析表明，有可能根据丙型肝炎病毒水平的初始反应来预测抗丙型肝炎治疗的长期反应在血浆中。在这些受试者中使用聚乙二醇化干扰素与利巴韦林的联合治疗，我们正在确定基因组和蛋白质组标记是否可以在开始治疗之前预测对治疗的反应。另一项临床试验将确定更频繁剂量的聚乙二醇化干扰素与利巴韦林联合用药是否可以增强丙型肝炎感染和艾滋病毒感染者对丙型肝炎治疗的病毒动力学反应。一项使用白蛋白偶联干扰素 α（Albuferon）治疗 HIV 感染患者丙型肝炎的新临床试验将于今年晚些时候开始入组。